SPH3127 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	2

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05770609 (ClinicalTrials.gov)	March 15, 2023	5/3/2023	A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Dose-finding Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Mild to Moderate Ulcerative Colitis	Mild to Moderate Ulcerative Colitis	Drug: SPH3127 Tablets with Dose A;Drug: SPH3127 Tablets with Dose B;Drug: SPH3127 Tablets placebo	Shanghai Pharmaceuticals Holding Co., Ltd	NULL	Not yet recruiting	18 Years	75 Years	All	108	Phase 2	China
2	NCT05019742 (ClinicalTrials.gov)	March 21, 2022	13/8/2021	Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis	A Double-Blind, Placebo-Controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis	Ulcerative Colitis	Drug: SPH3127;Drug: Placebo	Shanghai Pharma Biotherapeutics USA Inc.	NULL	Recruiting	18 Years	70 Years	All	30	Phase 2	United States